

**TABLE S1. Demographic and Clinical Characteristics of Participants at Baseline**

	Community Care (N = 181)		NAVIGATE (N = 223)				
Categorical Variables	N	%	N	%	F	Df	p-value <sup>1</sup>
Male	120	66	173	78	3.86	1, 370	0.05
Race					1.28	2, 336	0.28
White	80	44	138	62			
African American	89	49	63	28			
Other	12	7	22	10			
Hispanic ethnicity	18	10	55	25	3.24	1, 370	0.07
Type of insurance					1.28	2, 333	0.28
Private	27	15	55	25			
Public	66	37	61	27			
Uninsured	88	49	104	47			
Diagnosis					0.58	5, 234	0.72
Schizophrenia	101	56	113	51			
Schizoaffective bipolar	13	7	11	5			
Schizoaffective depressive	25	14	32	14			
Schizophreniform provisional or definite	24	13	43	19			
Brief psychotic disorder	1	1	1	1			
Psychotic disorder NOS	17	9	23	10			
Lifetime alcohol use					2.49	2, 336	0.08
Did not meet criteria	123	68	134	60			
Met abuse criteria	16	9	36	16			
Met dependence criteria	42	23	53	24			
Lifetime cannabis use					146	2, 336	0.23
Did not meet criteria	123	68	137	61			
Met abuse criteria	21	12	39	18			
Met dependence criteria	37	20	47	21			
Prescribed one or more antipsychotics at consent	155	86	182	82	0.36	1, 370	0.55
Number of prior hospitalizations					3.91	1, 368	0.05
0	34	19	54	24			
1	75	41	106	48			
2	32	18	37	17			
3 or more	40	22	24	11			

	Community Care (N = 181)		NAVIGATE (N = 223)				
Continuous Variables	Mean	SD	Mean	SD	F	Df	p-value <sup>1</sup>
Age	23.08	4.90	23.18	5.21	0.14	1, 370	0.71
Duration of untreated psychosis (weeks)	211.43	277.49	178.91	248.73	0.97	1, 369	0.33
Heinrichs-Carpenter Quality of Life Scale Total score	54.77	18.99	50.89	18.44	2.70	1, 369	0.10
Positive and Negative Syndrome Scale Total score	74.54	14.87	78.32	14.95	5.56	1, 369	0.02
Calgary Depression Scale for Schizophrenia	4.66	4.30	4.65	4.27	0.01	1, 369	0.99
Clinical Global Impressions Scale-severity of illness	3.96	0.83	4.12	0.80	3.37	1, 369	0.07
Duration of lifetime anti-psychotic medication at consent (days)	48.46	48.98	40.60	42.88	2.74	1, 369	0.10

<sup>1</sup> p values were adjusted for the clustered design by using linear, negative binomial, logit or generalized logit mixed effects model with cluster-specific random effects

**TABLE S2. Presence of Specific Side Effects**

Side effect group	Odds ratio between conditions <sup>2</sup>	95% Confidence Interval of odds ratio		Effect size for difference	Comparison across treatments				
					F value	Df		P-value unadjusted	P-value adjusted for multiple comparisons
sedation	0.500	0.295	0.846	-0.3821521	7.19	1	32	0.0115	0.0435
extrapyramidal symptoms	0.694	0.481	1.001	-0.2013912	4.13	1	32	0.0504	0.0605
anticholinergic side effects	0.582	0.380	0.892	-0.2984260	6.68	1	32	0.0145	0.0435
increased appetite or weight gain	0.719	0.533	0.970	-0.1818801	5.02	1	32	0.0321	0.0567
sexual problems	0.629	0.406	0.973	-0.2556093	4.70	1	32	0.0378	0.0567
Menstrual problems	0.608	0.274	1.347	-0.2743305	1.63	1	31	0.2113	0.2113

<sup>1</sup> The models included treatment condition, time and the treatment-by-time interaction. No significant treatment-by-time interaction was revealed in any analysis.

<sup>2</sup> Odds ratios less than 1.0 indicate more likelihood of being reported at Community Care sites; ratios greater than 1.0 indicate more likelihood of being reported at NAVIGATE sites